ClinicalTrials.gg
Not yet recruitingNCT06382467Updated Apr 24, 2024

Comparison of Remimazolam and Propofol Combination vs. Propofol in IOM

A Phase 4 interventional study of Remimazolam besylate + propofol MCT and Propofol MCT in Neurologic Disorder, sponsored by Chung-Ang University Gwangmyeong Hospital. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-04-24.

Sponsored by Chung-Ang University Gwangmyeong Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

This study aims to compare total intravenous anesthetic agents: combined remimazolam and propofol vs. propofol monotherapy. The comparison parameters are intraoperative hypotension, patient's involuntary movement, neurophysiological monitoring quality, onset time, recovery time, and postoperative rescue anti-emetics requirements.

Read the detailed description

This study hypothesizes that the combination regimen of remimazolam and propofol as total intravenous anesthesia in neurosurgical procedures requiring neurophysiological monitoring can reduce the incidence of hypotension compared to propofol monotherapy while providing comparable levels of neurophysiological monitoring and surgical conditions. With this hypothesis, the study aims to compare the frequency, severity, and duration of hypotension, frequency of patient movement, and appropriateness of neurophysiological monitoring between the combination therapy of remimazolam and propofol and propofol monotherapy in total intravenous anesthesia.

02

Conditions studied

  • Neurologic Disorder
03

In context

Nervous System Diseases

759 studies on the registry are indexed under Nervous System Diseases; 217 are open to participants now.

This study's planned enrollment of 56 is close to the median of 55 across 496 interventional studies indexed under Nervous System Diseases.

Browse Nervous System Diseases studies →

Lead sponsor

Chung-Ang University Gwangmyeong Hospital is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 19 and above with planned neurosurgical procedures requiring neurophysiological monitoring, classified as (ASA) physical status classification 1, 2, or 3 in the United States.

Exclusion criteria

Exclusion Criteria:

  1. Patients who refuse to participate in the study.
  2. Patients who are pregnant or lactating.
  3. Patients with to the drugs or to soy, peanuts, or Dextran 40.
  4. Patients with acute narrow-angle glaucoma.
  5. Patients with alcohol or drug dependence.
  6. Patients with hepatic impairment classified as class C.
  7. Patients with lactose intolerance.
  8. Patients requiring emergency surgery.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Combination group

    Combination regimen (remimazolam plus propofol)

    Drug: Remimazolam besylate + propofol MCT

  • Active comparator
    Propofol group

    Propofol monotherapy

    Drug: Propofol MCT

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of intraoperative hypotension

    mean arterial pressure \< 65mmHg

    Time frame: operation day - postoperative 1 day

Secondary outcomes

  1. Amount and number of inotropic agents

    intraoperative inotropics amount (phenylephrine(mcg), ephedrine(mg), norepinephrine(mcg), dopamine(mg))

    Time frame: operation day - postoperative 1 day

  2. Incidence of participants' intraoperative involuntary movement

    number of patients involuntary movement during operation (ex. no movement:0 , 3 times of movement: 3)

    Time frame: operation day - postoperative 1 day

  3. scores of neurophysiologic monitoring quality

    0-5 scale of neurophysiologic monitoring quality, scored by neurophysiologic monitoring technologist (poor: 0, good: 5)

    Time frame: operation day - postoperative 1 day

  4. onset time of study drugs

    time from administration of study drugs(remimazolam+propofol or propofol) to Bispectral index value \< 60

    Time frame: operation day - postoperative 1 day

  5. The administration number of rescue anti-emetic agents

    postoperative rescue anti-emetic agents (ramosetron, palonosetron, metoclopramide) requirements

    Time frame: operation day - postoperative 3 day

  6. Time-weighted average of intraoperative hypotension

    (depth of hypotension in millimeters of mercury below a MAP of 65mmHg × time in minutes spent below a MAP of 65mmHg)÷total duration of operation in minutes

    Time frame: operation day - postoperative 1 day

  7. recovery time of study drugs (remimazolam+propofol or propofol)

    time from discontinuation of study drugs(remimazolam+propofol or propofol) to Bispectral index value \> 60

    Time frame: operation day - postoperative 1 day

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2024; primary completion for May 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2024
First posted
Apr 24, 2024
StartEst.
May 2024
Primary completionEst.
May 2025
CompletionEst.
Jun 2025
Last update
Apr 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06382467
Lead sponsor
Chung-Ang University Gwangmyeong Hospital
Responsible party
Jiwon Han (Assistant professor, Chung-Ang University Gwangmyeong Hospital) — Principal investigator
First posted
Apr 24, 2024
Start date
May 2024 (estimated)
Primary completion
May 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Apr 24, 2024

Study contacts

Jiwon Han, Pf.
Contact
yesuroon@gmail.com
821034471988

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Remimazolam besilate · Propofol

Start the discussion